Skip to content
Single Family OfficeInvests its own capital directly in companiesLAST VERIFIED Oct 2026 · 8 SOURCES

Parvilla Investissements

Also known as Parvilla Investissements SAS

SAS created in 2006 by ex-PAI Partners senior partner Jean-Marie Fabre and controlled by him; invests in LBO funds and co-investments (70%) and venture/life-science funds (30%).

USEFUL FOR Fund managers raising capital · Founders · Business owners seeking a long-term partner · Co-investors

Personal investment company of Jean-Marie Fabre. Not to be confused with Parvilla SAS, the AMF-authorised manager it owned until 2019, now renamed Bluester Capital.

Family & background

HEADQUARTERS
Neuilly-sur-Seine, France
FOUNDED
2006

Investment approach

SECTORS
Biotech & Life SciencesHealthTechSoftware & SaaSIndustrial & Manufacturing
GEOGRAPHY
FranceUnited KingdomGermanySwitzerlandEurope
STAGES
SeedSeries ASeries BBuyout
ROUTES
Companies (own capital) · Funds (as LP)
STRATEGIES
Private equityFunds (as LP)Venture capitalDirect investments

Overview

Parvilla Investissements is a simplified joint-stock company created in 2006 by Jean-Marie Fabre, a former senior partner of PAI Partners, to invest in private equity, and it is controlled by its founder. It was the sole shareholder of Parvilla SAS, an AMF-authorised manager that raised the Parvilla I–III funds, until 1 October 2019, when it left that company (since renamed Bluester Capital). It now invests about 70% in small and lower mid-market LBO, through funds and co-investments, and about 30% in venture and life-science funds, in France and northern Europe. Its fund commitments include PAI Europe VII, Eurazeo PME V, Argos XI, Sofinnova XI and LSP 7.

Holdings & investments (40)

  • Sparring Capital Fund 3
    since 2025 · (fund commitment)
  • Eurazeo PME V
    since 2025 · (fund commitment)
  • Afinum X
    since 2025 · (fund commitment)
  • Argos XI
    since 2025 · (fund commitment)
  • Sofinnova XI
    since 2024 · (fund commitment)
  • Raith (via Capiton's Quantum vehicle)
    Deep Tech · since 2023
  • AEMTEC (via Capiton's Quantum vehicle)
    Deep Tech · since 2023
  • NeoXam (via an Eurazeo PME vehicle)
    Fintech · since 2023
  • Efeso (via an Eurazeo PME vehicle)
    since 2023
  • Parquest Capital III
    since 2022 · (fund commitment)
  • PAI Strategic Partnerships (Froneri, Marcolin)
    since 2022 · (fund commitment)
  • Eurazeo PME IV-B
    since 2021 · (fund commitment)
  • Capiton VI
    since 2021 · (fund commitment)
  • Sofinnova X
    since 2021 · (fund commitment)
  • Elaia Alpha 2
    since 2021 · (fund commitment)
  • LSP 7
    since 2021 · (fund commitment)
  • Xpath (via a Techlife Capital vehicle)
    HealthTech · since 2021
  • Bluester IV
    since 2020 · (fund commitment)
  • MCH Iberian Capital Fund V
    since 2020 · (fund commitment)
  • Sparring Capital Fund 2
    since 2020 · (fund commitment)
  • IQ Growth
    since 2020 · (fund commitment)
  • Sofinnova MD Start III
    since 2019 · (fund commitment)
  • Health for Life Capital II
    since 2019 · (fund commitment)
  • Vulcain (via a Nixen-managed vehicle)
    since 2019
  • PAI Europe VII
    since 2018 · (fund commitment)
  • Sofinnova IX
    since 2018 · (fund commitment)
  • LSP 6
    since 2018 · (fund commitment)
  • Kama
    Industrial & Manufacturing · since 2018
  • Litalsa
    Industrial & Manufacturing · since 2018
  • Premium Equity Partners
    since 2017 · (fund commitment)
  • Sofinnova Cross Over
    since 2017 · (fund commitment)
  • LSP HEF 2
    since 2017 · (fund commitment)
  • Parvilla III
    since 2016 · (fund commitment)
  • Sofinnova VIII
    since 2016 · (fund commitment)
  • Alven V
    since 2016 · (fund commitment)
  • Elaia Delta
    since 2016 · (fund commitment)
  • Blackfin II
    since 2015 · (fund commitment)
  • Parvilla II
    since 2012 · (fund commitment); largely divested
  • Garavilla
    Food & Agriculture · since 2010 · Exited
  • Parvilla I
    since 2008 · (fund commitment); divested

People

  • Jean-Marie Fabre
    Founder and controlling shareholder · source

Frequently asked questions

Parvilla Investissements is a single family office based in Neuilly-sur-Seine, France, founded in 2006.

Parvilla Investissements invests directly and through funds. Capital origin: one family's own capital. Stated strategies include private equity, funds (as lp), venture capital and direct investments.

Parvilla Investissements invests at Seed, Series A, Series B and Buyout stages in Biotech & Life Sciences, HealthTech, Software & SaaS and Industrial & Manufacturing.

Key people at Parvilla Investissements include Jean-Marie Fabre (Founder and controlling shareholder).

Parvilla Investissements's disclosed holdings and investments include Parvilla I, Parvilla II, Parvilla III, Bluester IV, Blackfin II, Premium Equity Partners, PAI Europe VII and MCH Iberian Capital Fund V, among others.